C12N 2710/16122
New viral proteins or individual genes, new structural or functional aspects of
Official title: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
C12N2710/16122 (New viral proteins or individual genes, new structural or functional aspects of) appears on 277 US grants and 318 published applications in this corpus.
Search patents in C12N- Granted patents
- 277
- Published applications
- 318
- Assignees
- 191
- Inventors
- 612
- Latest grant
- 12 May 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1987 | 1 | 0 |
| 1988 | 1 | 0 |
| 1989 | 0 | 0 |
| 1990 | 1 | 0 |
| 1991 | 0 | 0 |
| 1992 | 3 | 0 |
| 1993 | 2 | 0 |
| 1994 | 2 | 0 |
| 1995 | 3 | 0 |
| 1996 | 8 | 0 |
| 1997 | 6 | 0 |
| 1998 | 23 | 0 |
| 1999 | 13 | 0 |
| 2000 | 14 | 0 |
| 2001 | 14 | 2 |
| 2002 | 5 | 8 |
| 2003 | 12 | 14 |
| 2004 | 7 | 15 |
| 2005 | 3 | 10 |
| 2006 | 5 | 6 |
| 2007 | 5 | 2 |
| 2008 | 6 | 8 |
| 2009 | 3 | 6 |
| 2010 | 2 | 9 |
| 2011 | 3 | 10 |
| 2012 | 5 | 8 |
| 2013 | 6 | 13 |
| 2014 | 6 | 14 |
| 2015 | 7 | 10 |
| 2016 | 11 | 11 |
| 2017 | 10 | 13 |
| 2018 | 9 | 14 |
| 2019 | 12 | 15 |
| 2020 | 9 | 20 |
| 2021 | 12 | 27 |
| 2022 | 13 | 19 |
| 2023 | 6 | 23 |
| 2024 | 12 | 10 |
| 2025 | 13 | 21 |
| 2026 | 4 | 10 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Methods and vaccines for inducing immune responses to multiple different MHC molecules12 May 2026US 12,622,956 B2Mayo Foundation for Medical Education and Research
- Transient expression of biologic materials17 Mar 2026US 12,576,041 B1
- Fusion protein of pentamer and gB of cytomegalovirus, and vaccine containing said fusion protein10 Mar 2026US 12,569,552 B2KM Biologics Co., Ltd.
- Compositions and methods for treating HIV infection and reversing HIV latency6 Jan 2026US 12,514,921 B2University of Pittsburgh—Of the Commonwealth System of Higher Education
- Hepatitis B virus vaccines2 Dec 2025US 12,485,168 B2Triad National Security, LLC
- Modified cytomegalovirus proteins and stabilized complexes27 Aug 2026US 2026/0250330 A1Glaxosmithkline Biologicals SA
- Human cytomegalovirus gb polypeptide20 Aug 2026US 2026/0240988 A1Pfizer Inc.
- Recombinant vaccinia virus encoding one or more natural killer cell and t lymphocyte inhibitors16 Jul 2026US 2026/0199414 A1Turnstone Biologics Corp.
- Herpesviral combination therapy for targeting cancer cells and cancer associated stromal cells11 Jun 2026US 2026/0158087 A1Mayo Foundation for Medical Education and Research
- Prefusion-stabilized cmv gb proteins21 May 2026US 2026/0139009 A1Board of Regents, The University of Texas System
Most cited
By later US patents
- Deoxyribonucleic acid segment from a virus193US 4,968,615 ACiba-Geigy Corporation · 1990
- NYVAC vaccinia virus recombinants comprising heterologous inserts137US 5,494,807 AVirogenetics Corporation · 1996
- Human cytomegalovirus RNA vaccines130US 10,064,935 B2ModernaTX, Inc. · 2018
- Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence128US 5,833,975 AVirogenetics Corporation · 1998
- Methods for capture and selective release of nucleic acids using weakly basic polymer and amplification of same124US 5,582,988 AJohnson & Johnson Clinical Diagnostics, Inc. · 1996